Format

Send to

Choose Destination
See comment in PubMed Commons below
Urol Oncol. 2010 Nov-Dec;28(6):624-7. doi: 10.1016/j.urolonc.2008.10.012. Epub 2008 Dec 30.

Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer.

Author information

1
Laboratory of Medical Investigation (LIM55), Urology Department, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Abstract

OBJECTIVE:

Prostate cancer (PCa) is the most frequent tumor in males in Brazil. Single nucleotide polymorphisms (SNP) have been demonstrated in the promoter region of matrix metalloproteinases (MMPs) genes and have been associated with development and progression of some cancers. In this study, our aim was to investigate a possible relation between polymorphism of the promoter region of the MMP2 gene and classical prognostic parameters in prostate cancer.

MATERIALS AND METHODS:

Genomic DNA was extracted using conventional protocols. The DNA sequence containing the polymorphic site was amplified by real-time polymerase chain reaction, using fluorescent probes (TaqMan).

RESULTS:

In patients with tumors of a higher stage (pT3), a polymorphic allele in the MMP2 gene was more frequent (P = 0.026) than in patients with lower tumor stage. A polymorphic allele in the MMP2 gene was more frequent in Gleason ≥ 7 than in Gleason ≤ 6 (P = 0.042).

CONCLUSIONS:

We conclude that MMP2 polymorphism can be used together with pathological stage and Gleason score to identify patients with worse prognosis. Our results illustrate the potential use of MMP2 SNP as a molecular marker for prostate cancer.

PMID:
19117773
DOI:
10.1016/j.urolonc.2008.10.012
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center